S100A8

Case Study 1: Roseanne Raphael, 2016

Heart failure with ejection fraction (HFpEF) is a syndrome resulting from several co-morbidities in which specific mediators are unknown. The platelet proteome responds to disease processes. The researchers hypothesize that the platelet proteome will change composition in patients with HFpEF and may uncover mediators of the syndrome.

Mass spectrometry identified 6102 proteins with five scans with peptide probabilities of ≥0.85. Of the 6102 proteins, 165 were present only in symptomatic subjects, 78 were only found in outpatient subjects and 157 proteins were unique to the control group. The S100A8 protein was identified consistently in HFpEF samples when compared with controls. They validated the fining that plasma S100A8 levels are increased in subjects with HFpEF (654 ± 391) compared to controls (352 ± 204) in an external cohort (p = 0.002). Recombinant S100A8 had direct effects on the electrophysiological and calcium handling profile in human induced pluripotent stem cell-derived cardiomyocytes.

Fig1. Representative MS/MS scan for S100A8 peptide sequence ALNSIIDVYHK.

Fig2. Spontaneous Ca2+ transients recorded from human cardiomyocytes treated with rS100A8 as indicated by the blue line.

Case Study 2: Andrew P Coveney, 2015

Myeloid-related protein 8 (Mrp8) is the active component of Mrp8/14 protein complex released by phagocytes at the site of infection and stimulates inflammatory responses. However, it is unclear whether Mrp8 could induce self-tolerance and cross-tolerance to bacterial infection. Here the researchers report that Mrp8 triggered TNF-α and IL-6 release via a Toll-like receptor 4 (TLR4)-dependent manner. Pre-stimulation of murine macrophages and human monocytes with Mrp8 induced self-tolerance to Mrp8 re-stimulation and cross-tolerance to lipopolysaccharide (LPS), bacterial lipoprotein (BLP), gram-negative and gram-positive bacterial challenges, with substantially attenuated TNF-α and IL-6 release. Moreover, Mrp8 tolerisation significantly reduced serum TNF-α and IL-6, increased polymorphonuclear neutrophil (PMN) recruitment and accelerated bacterial clearance, thus protecting mice against LPS-induced lethality and cecal ligation and puncture (CLP)-induced polymicrobial sepsis. In addition to TLR4, TLR2 also contributed to Mrp8-induced inflammatory response and tolerance. Down-regulation of phosphorylated p38 by Mrp8 pre-stimulation was predominantly responsible for the intracellular mechanism of Mrp8-induced tolerance.

Fig3. Peritoneal macrophages isolated from C3H/HeN mice were pre-stimulated with increasing doses of mMrp8 for 18 h and re-stimulated with 5 μg/ml mMrp8 for 6 h.

Fig4. Mrp8 pre-stimulation attenuates p38 phosphorylation in human monocytes re-stimulated with either Mrp8.

Fig1. S100A8/A9 in tumor progression. (Geetha Srikrishna, 2012)

Fig2. Interactions between obesity, hyperglycemia, dexamethasone and S100A8/A9 in COVID19. (Nordin M J Hanssen, 2021)

S100A8 involved in several pathways and played different roles in them. We selected most pathways S100A8 participated on our site, such as , which may be useful for your reference. Also, other proteins which involved in the same pathway with S100A8 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.

S100A8 has several biochemical functions, for example, RAGE receptor binding, Toll-like receptor 4 binding, arachidonic acid binding. Some of the functions are cooperated with other proteins, some of the functions could acted by S100A8 itself. We selected most functions S100A8 had, and list some proteins which have the same functions with S100A8. You can find most of the proteins on our site.

S100A8 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with S100A8 here. Most of them are supplied by our site. Hope this information will be useful for your research of S100A8.

S100A9; GAPDH; ESR1; NOS2; PPP2R2B